Eli Lilly and Company has acquired Verve Therapeutics Inc., a Boston-based clinical-stage company developing genetic ...

Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Verve Therapeutics, Inc.

Eli Lilly's acquisition of Vere Therapeutics promises to revolutionize cardiovascular care with innovative one-time gene ...

Eli Lilly and Company (NYSE: LLY) and Verve Therapeutics, Inc. (NASDAQ: VERV) today announced that the tender offer to ...

Eli Lilly and Company (LLY) announced the successful completion of its acquisition of Verve Therapeutics. (VERV). Verve is a Boston-based ...

We came across a bullish thesis on Verve Therapeutics, Inc. on Stock Region Research’s Substack by Stock Region. In this article, we will summarize the bulls’ thesis on VERV. Verve Therapeutics, ...

Shares of Verve Therapeutics (VERV 1.28%) sank as much as 30.7% this week, according to data from S&P Global Market Intelligence.The gene-editing company focused on the cardiovascular market ...

Verve Therapeutics (NASDAQ: VERV) is up 16.5% for the week. The biotech stock, which was as low as $41.52 a share on Monday, climbed as high as $48.39 by Thursday. For a relatively new stock (it ...

If Verve Therapeutics' dramatic stock price activity left your head spinning, you're not alone. Let's take a closer look at what happened so it isn't so easy to get caught off guard in the future.

Verve Therapeutics, a next-generation cardiovascular company, today announced the presentation of new preclinical proof-of-concept data in non-human p ...

If Verve Therapeutics' dramatic stock price activity left your head spinning, you're not alone. Let's take a closer look at what happened so it isn't so easy to get caught off guard in the future.